Metabolomics research highlights molecules important for cancer prevention, diagnosis, and treatment.

Transplanted CAR stem cells persisted long term and showed multilineage engraftment in tissues that harbor HIV.

Researchers developed a new CAR T-cell therapy that targets specific growth factor receptors in glioblastoma to eliminate brain tumors.

Pairing CARs with a synthetic receptor makes T cells more lethal tumor killers.

Erik Steinfelder and Bogi Eliasen will examine the importance of biobanking in precision medicine, from early-stage research to diagnostics and treatments.

Sensors encapsulated with oral chemotherapy drugs help patients and physicians keep track of treatments.

Meet some of the people featured in the July/August 2019 issue of The Scientist.

Not only can artificial intelligence revolutionize healthcare, it could help restore the doctor-patient relationship.

The three-dimensional cell cultures are still in the development phase, but researchers are excited about their use to predict patients’ responses to various treatment options.

Eric Topol, founder and director of Scripps Research Translational Institute and Reading Frames author, discusses the future of the doctor-patient bond in an era of artificial intelligence–driven medicine.

This month’s Profilee, Dana-Farber Cancer Institute researcher Stuart Orkin, talks about treating kids with cancer and other blood disorders.

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

The medicine increases the activity of a deficient enzyme in certain patients with the condition.

Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.

The agency says it has taken various steps to ensure the privacy of participants’ data. 

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

The publicly available database found nearly a third of samples included mutations targeted by either approved drugs or therapies in clinical trials. 

The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.